Table I.
Associations between cofilin expression and clinicopathological features in breast cancer.
| Cofilin staining intensity | ||||||
|---|---|---|---|---|---|---|
| Factor | Number | 0 | 1 | 2 | 3 | P-value |
| All, n (%) | 310 | 53 (17) | 114 (37) | 92 (30) | 51 (16) | |
| Age, yearsa | 54 (29–88) | 50.5 (29–83) | 54 (31–88) | 57 (31–87) | 56 (37–88) | 0.055b |
| Tumor size, mma | 30 (10–150) | 30 (10–100) | 30 (14–130) | 30 (10–150) | 35 (10–100) | 0.294b |
| NHG, n (%) | 0.030d | |||||
| I | 19 (6) | 6 (32) | 8 (42) | 5 (26) | 0 (0) | |
| II | 210 (68) | 36 (17) | 83 (40) | 61 (29) | 30 (14) | |
| III | 70 (22) | 10 (14) | 21 (30) | 19 (27) | 20 (29) | |
| Missing | 11 (4) | |||||
| Nodal status, n (%) | 0.082c | |||||
| N0 | 141 (45) | 21 (15) | 48 (34) | 49 (34) | 23 (16) | |
| N1 | 86 (28) | 14 (16) | 33 (38) | 21 (24) | 18 (21) | |
| N2 | 56 (18) | 11 (20) | 26 (46) | 13 (23) | 6 (11) | |
| N3 | 21 (7) | 7 (33) | 2 (10) | 8 (38) | 4 (19) | |
| Missing | 6 (2) | |||||
| ER status, n (%) | 0.084c | |||||
| Positive | 191 (62) | 26 (14) | 76 (40) | 62 (32) | 27 (14) | |
| Negative | 114 (37) | 24 (21) | 36 (32) | 30 (26) | 24 (21) | |
| Missing | 5 (2) | |||||
| PR status, n (%) | 0.176c | |||||
| Positive | 139 (45) | 21 (15) | 56 (40) | 45 (32) | 17 (12) | |
| Negative | 168 (54) | 31 (18) | 56 (33) | 47 (28) | 34 (20) | |
| Missing | 3 (1) | |||||
| Ki67 status, n (%) | 0.001c | |||||
| >14% | 99 (32) | 11 (11) | 29 (29) | 32 (32) | 27 (27) | |
| ≤14% | 211 (68) | 42 (20) | 85 (40) | 60 (28) | 24 (13) | |
| Missing | 0 (0) | |||||
| HER2 status, n (%)e | 0.000d | |||||
| Strong | 77 (25) | 2 (2) | 29 (38) | 28 (36) | 18 (23) | |
| Weak | 233 (75) | 51 (22) | 85 (36) | 64 (27) | 33 (14) | |
| Missing | 0 (0) | |||||
a
Data presented as mean (range).
b
One-factor analysis of variance.
c
Pearson χ2 test, 2-tailed P-value.
d
Fisher's excat test.
e
Weak (score 0–1, or FISH−), strong (score 3, or FISH+). NGH, Nottingham histological grade; FISH, fluorescence in situ hybridization.